Lifeward

LFWD · NASDAQ

$6.06+$0.2431 (+4.18%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $5.82

LFWD analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $20.40 (+236.6% upside)

Low: $10.10
Now: $6.06
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

LFWD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Mar 19, 2026	Maintains	Buy	$4.50 → $10.00	43%
HC Wainwright & Co.	Nov 18, 2025	Maintains	Buy	$13.00 → $4.50	43%

The case for and against

Updated Aug 7, 2025

Bull case

Lifeward Ltd is projected to see its total revenues rise significantly, from $29.0 million in 2025 to $336.5 million by 2032, indicating a robust growth trajectory fueled by the increased placement of ReWalk and Alter-G systems along with improved reimbursement processes. The company demonstrated notable financial performance in the fourth quarter of 2024, achieving $7.5 million in revenue, marking a 23% quarter-over-quarter growth from the previous quarter and highlighting management's fiscal prudence. Additionally, the anticipated launch of the next-generation ReWalk 7.0 in 2025 and the expanded partnership with MYOLYN to enhance patient access to the MyoCycle FES Cycling Therapy System suggest promising avenues for sustainable revenue growth in the coming years.

Bear case

Lifeward Ltd is facing significant financial challenges, evidenced by recurring losses associated with the extinguishment of debt, which negatively impacts its cash flow and overall financial health. This situation suggests ongoing difficulties in managing debt obligations, raising concerns about the company's ability to sustain operations and pursue growth initiatives. Furthermore, the absence of clarity surrounding its financial recovery strategies may lead to heightened uncertainty among investors regarding the company’s long-term viability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.